Rua Bioscience Limited — AGM Information 2021

Oct 18, 2021

==> picture [237 x 98] intentionally omitted <==

Annual Shareholders Meeting October 2021

Rua Bioscience Limited (Rua) is a New Zealand pharmaceutical company aiming to be a leading producer of cannabinoid derived medicines. This presentation and the information contained in or accompanying this presentation are not, and are under no circumstances to be construed as, an invitation to subscribe for, or an offer of, shares, securities or financial products to any person, in any country or the basis for a contract, financial advice, other advice or recommendation to conclude any transaction for the purchase or sale of any security, loan or other instrument. This presentation has not been independently verified. Neither Rua nor any of its directors, officers, shareholders, advisors, agents or employees make any representation or warranty as to the accuracy or completeness of the information contained in this presentation and those parties shall have no liability for any statement, opinion, information or matters arising out of, contained in, or for any omissions from, or failure to correct or update any information in, this presentation or any other communications transmitted to you in relation to this presentation.

==> picture [47 x 25] intentionally omitted <==

2

==> picture [960 x 481] intentionally omitted <==

----- Start of picture text -----

Company
Overview and
Chair’s Address
----- End of picture text -----

==> picture [47 x 25] intentionally omitted <==

3

==> picture [960 x 478] intentionally omitted <==

----- Start of picture text -----

Panapa Ehau Manu Caddie
Ngāti Uepohatu, Ngāti Ngāti Pūkenga, Ngāti Hauā
Porou Kaihautu - Innovation and
Director, Co-Founder Regulation, Co-Founder
----- End of picture text -----

==> picture [47 x 25] intentionally omitted <==

4

Our vision at Rua Bioscience is simple – to create cannabinoidderived medicines that change people’s lives; from right here in Te Tairāwhiti.

==> picture [47 x 25] intentionally omitted <==

Te Rautaki o Rua Our Strategy – Focus and Objectives

==> picture [74 x 166] intentionally omitted <==

Creating Unique Product and Plant IP

Developing New Products and Markets

• Create unique, sustainable and protected IP, cultivation techniques

• Develop commercially viable varieties of cultivars

• Use research partners to develop IP

• Create new, protected product formulations

• Develop new, attractive markets

• Achieve sustainable revenue

==> picture [75 x 74] intentionally omitted <==

Optimising Cultivation and Processing

• Achieve excellence in cultivation & processing techniques

• Develop cultivation partnerships to expand production

• Obtain licences and approvals for all processes, products, markets

==> picture [74 x 74] intentionally omitted <==

Developing our People

• Build a capable and committed team

• Create employment pathways for Te Tairāwhiti residents

Te Paori Ringatohu Board of Directors

==> picture [142 x 139] intentionally omitted <==

==> picture [142 x 140] intentionally omitted <==

==> picture [142 x 140] intentionally omitted <==

==> picture [142 x 139] intentionally omitted <==

==> picture [142 x 140] intentionally omitted <==

Independent Director, Director Independent Independent Chairman Co-Founder Ringatohu Director Director Heamana Kaiwhakaū / Whakatū Pū Ringatohu Ringatohu Whakatū Pū Ringatohu Wehe Kē Whakatū Pū Whakatū Pū Wehe Kē Ngāti Pehe Kē Pehe Kē Uepohatu, Appointed Appointed Ngāti Porou December Appointed Appointed August 2019. 2019. May 2019. Nov 2018. Appointed October 2017.

==> picture [47 x 25] intentionally omitted <==

7

==> picture [960 x 481] intentionally omitted <==

----- Start of picture text -----

Māwhiti mai ki ngā Whakatutukitanga
Achievements at a Glance
Successfully Built new Signed Received Exported first
listed on NZX. facilities in exclusive New commercial sample
Ruatorea and Zealand licence to grow medicinal
Tūranga supplier sales and supply cannabis
/Gisborne. agreement cannabis- flower to
with Nimbus derived Germany.
Health in medicines.
Germany.
----- End of picture text -----

==> picture [47 x 25] intentionally omitted <==

8

==> picture [960 x 481] intentionally omitted <==

----- Start of picture text -----

Māwhiti mai ki ngā Whakatutukitanga
Achievements at a Glance
Attracted key Announced Developed the Received Received GMP
staff critical to hyperspectral Rua commercial Certification of
the imaging Sustainability licence to grow our Gisborne
commercialisat project with Framework. and supply manufacturing
ion of Rua the University cannabis- facility and
operations. of Waikato. derived first product.
medicines.
----- End of picture text -----

==> picture [47 x 25] intentionally omitted <==

9

GEOGRAPHICAL SPREAD OF OUR SHAREHOLDING AS AT 30 JUNE 2021

AS AT 30 JUNE 2021 Te Tairāwhiti Nga Kaipupuri Hea l 37.23% of our Auckland Our Shareholders Shareholders l 20.58% of our l Hold 19.47% of Rua’s shares shareholders As at 30 June 2021: l Hold 17.37% of Bay of Plenty Rua’s shares • 2,901 shareholders l 6.45% of our Wellington • shareholders 97.59% of our l Hold 23.74% of shareholders reside in l 8.69% of our Rua’s shares New Zealand shareholders l Hold 17.51% of Canterbury • 37.23% reside in Te Rua’s shares Tairāwhiti l 6.48% of our shareholders l Hold 14.54% of Rua’s shares

Nga Kaipupuri Hea Our Shareholders

==> picture [19 x 22] intentionally omitted <==

==> picture [47 x 25] intentionally omitted <==

10

==> picture [960 x 481] intentionally omitted <==

----- Start of picture text -----

Nga Kaipupuri Hea
Our Shareholders
Top 10 Holders
1. Fang Group Investment Ltd
2. Hikurangi Bioactives Ltd Partnership
3. Tailorspace Capital Ltd
4. NZ Depository Nominee Ltd
5. Andrew Charles Williams
6. FNZ Custodians Ltd
7. Ridings Brothers Ltd
8. Custodial Services Ltd
9. Wakaroma A/C
10. Forsyth Barr Custodians Limited
----- End of picture text -----

==> picture [47 x 25] intentionally omitted <==

11

==> picture [960 x 481] intentionally omitted <==

----- Start of picture text -----

Chief Executive
Officer’s
Presentation
----- End of picture text -----

==> picture [47 x 25] intentionally omitted <==

12

Hanga Wāriu Creating Value

Good Manufacturing Practice (GMP) Certification

Globally recognised minimum standards for the manufacture of medicines.

Prerequisite for commercial production.

Key step on the path to revenue. Rua began audit in November 2020 and achieved GMP certification of the Gisborne Manufacturing site on 28th September 2021.

==> picture [480 x 324] intentionally omitted <==

==> picture [47 x 25] intentionally omitted <==

13

Hanga Wāriu Creating Value

Progress on Cultivation Optimization and Capacity

Well advanced in establishing our commercial cultivars.

Rua has signed three supply agreements with grower partners and an R&D supply agreement. Trial started with the East Coast Cannabis Company on site in October 2021.

==> picture [481 x 326] intentionally omitted <==

==> picture [47 x 25] intentionally omitted <==

14

Hanga Wāriu Creating Value

Research and Development

Rua announced a ground-breaking, twoyear research programme to investigate the application of hyperspectral technology to the cultivation and assessment of medicinal cannabis, paving the way for Rua to enter New Zealand's booming agritech sector.

==> picture [182 x 52] intentionally omitted <==

----- Start of picture text -----

Successful export of the first.
----- End of picture text -----

==> picture [481 x 325] intentionally omitted <==

==> picture [47 x 25] intentionally omitted <==

15

Ngā Pou Matua Senior Management

==> picture [142 x 139] intentionally omitted <==

==> picture [142 x 140] intentionally omitted <==

==> picture [142 x 140] intentionally omitted <==

==> picture [139 x 139] intentionally omitted <==

==> picture [141 x 140] intentionally omitted <==

==> picture [139 x 139] intentionally omitted <==

Chief Innovation and Chief Financial Chief Chief Research Chief Executive Regulation, Officer Operations Officer Commercial Officer Co-Founder Āpiha Officer Āpiha Officer Kaiwhakahāere Kaiwhakaū / Kaiwhakahāere Āpiha Kairangahau Āpiha Kaihoko Matua Kaihautu Pūtea Kaitohutohu Matua Matua Matua Ngāti Pūkenga, Ngāti Ruanui Ngāti Hauā

==> picture [47 x 25] intentionally omitted <==

16

Len Walker

Ng ā ti Porou, Aitanga-a-Hauiti, Te Wh ā nau-a-Apanui

Kaiwhakah ā ere hangahanga Cultivation Manager MBA

==> picture [361 x 480] intentionally omitted <==

17

Te Matapae o te Mākete o Aotearoa New Zealand Market Forecast

New Zealand is growing rapidly off a small base.

The number of packs of CBD products supplied in New Zealand in the year to 30 June 2021 was over 31,000. This compares to just 2,000 in 2018.

==> picture [58 x 58] intentionally omitted <==

CBDPER ANNUMPRODUCTSTO THESUPPLIED NZ 31,000 MARKET

==> picture [121 x 352] intentionally omitted <==

==> picture [198 x 228] intentionally omitted <==

----- Start of picture text -----

21,964
6,993
----- End of picture text -----

2019 2020 2021

==> picture [47 x 25] intentionally omitted <==

Source: Ministry of Health, 2021

18

Ngā mea Angitū o te Mākete ki Tiāmana German Market Opportunities

Germany is currently the largest single market for GMP (pharmaceutical) grade cannabis globally.

Public health insurance coverage of prescriptions reached €90M in the first half of 2021.

With over €45M reimbursed in Q2 2021, it was a record quarter, increasing 2.5% over Q1 2021 and up 13% from Q2 2020.

184,499 cannabis prescriptions were covered by the public health system in H1 2021 (average of €487 per prescription).

==> picture [59 x 59] intentionally omitted <==

==> picture [136 x 39] intentionally omitted <==

----- Start of picture text -----

MARKET SHARE OF
CANNABIS DRUGS IN
GERMANY
----- End of picture text -----

==> picture [25 x 170] intentionally omitted <==

----- Start of picture text -----

50%
40%
30%
20%
----- End of picture text -----

10%

JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC

Flower Full Spectrum Extract Other - Pharmaceuticals

Graph Source: Prohibition Partners, 2021 Data Source: German National Association of Statutory Health Insurance Funds

==> picture [47 x 25] intentionally omitted <==

19

Ngā mea Angitū o te Mākete o te Ao Global Market Opportunities

CANNABIS LEGALISATION TO MARCH 2021

• Available via import* Production legalised Treatment legalised Medical and Recreational adult use legalised†

• In exceptional circumstances

• † Includes countries with potential upcoming legalisation or upcoming pilot programme

Source: The Economist, 2021

==> picture [47 x 25] intentionally omitted <==

20

Ārahitanga Whakahāere Guidance on Timing

Q4 Q1 Late Q1 Early Q2 Dec 2022 2022 2022 2023 New Markets First First Self-Sustaining End of Cash Domestic Revenue Export Revenue Revenue Runway Expanded export Product available Product made With Based on our strategy for New Zealand available to German approximately predicted cash burn patients as a patients through three products rate (excluding prescription-only Nimbus Health. in the market. revenue). medicine.

==> picture [47 x 25] intentionally omitted <==

21

Ngā mea Angitū me ngā Wero Opportunities and Challenges

Opportunities

• Markets opening around the world

• Growing body of clinical evidence

Challenges

• Decades of stigma

• Meeting Minimum Quality Standards

• Expansion of foreign markets

==> picture [481 x 326] intentionally omitted <==

==> picture [47 x 25] intentionally omitted <==

22

==> picture [960 x 481] intentionally omitted <==

----- Start of picture text -----

Whai Hua mo Apōpō
Towards Sustainability
Hamish Harris
Ngāti Porou, Nga Puhi
Plant Health Specialist
----- End of picture text -----

==> picture [47 x 25] intentionally omitted <==

23

==> picture [960 x 481] intentionally omitted <==

----- Start of picture text -----

Whakapā atu ki te Iwi Whānui
Community Engagement
----- End of picture text -----

==> picture [47 x 25] intentionally omitted <==

24

==> picture [960 x 481] intentionally omitted <==

----- Start of picture text -----

Annual Results
----- End of picture text -----

==> picture [47 x 25] intentionally omitted <==

25

Māwhiti mai ki ngā	Māwhiti mai ki ngā	Hua Nui
Results at a Glance
Cash and	Funds	Other	Investment	Investment	Loss after
Investments	Raised	Income	in R&D	in Property,	Tax
$16.4M	$20M	$451K	$1.9M	Plant and Equipment	-$4.42M
				$6.17M

==> picture [47 x 25] intentionally omitted <==

26

==> picture [121 x 122] intentionally omitted <==

Loss after Tax

==> picture [47 x 25] intentionally omitted <==

27

==> picture [121 x 122] intentionally omitted <==

Net Assets

==> picture [47 x 25] intentionally omitted <==

28

==> picture [122 x 121] intentionally omitted <==

Net Cash Inflow

==> picture [47 x 25] intentionally omitted <==

29

==> picture [960 x 455] intentionally omitted <==

Nga mihi, e noho rā

==> picture [224 x 86] intentionally omitted <==